Fluorenone Drug for Treatment of Combat-Related Traumatic Optic Neuropathy
Abstract
Traumatic optic neuropathy (TON) is a frequent cause of significant visual loss after combat-related frontal head trauma. There is no clinically proven therapy for improving visual outcomes in TON patients. Identification of new treatment options for TON is of highest priority. Our goal is to conduct studies needed to advance the proposed drug candidate, B-3(+), to clinical development for the TON indication. The following specific aims have been identified in order to attain the study objective: Develop a standard in vitro ADMET package required to support pre-clinical and clinical development of the drug candidate (Specific Aim 1); Conduct systemic and ocular pharmacokinetic studies in beagle dogs; use blood samples collected in PK studies for assessing drug nephrotoxicity (Specific Aim 2); Expand upon existing pre-clinical efficacy data and develop a robust efficacy package that can convincingly justify compound testing in patients with traumatic optic neuropathy (Specific Aim 3).
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2020
- Accession Number
- AD1126411
Entities
People
- Konstantin Petrukhin